The news. The narrative. The timeline.
Bureau: Chicago
Doustdar's 200K-a-week Wegovy pill holds while Lilly's Foundayo prints 7,335 in Week 4 against a 90,000-script bar — and BMO's 12% bear is now the consensus read.
Day fourteen of the FCC's thirty-day early-license-renewal order leaves Disney fourteen days to file ABC station renewals; Commissioner Gomez calls it 'unprecedented, unlawful and going nowhere.'
Lancet Psychiatry's 95K-Swedish-cohort GLP-1 study lands on an FDA desk that already moved in January to drop the suicidal-behavior warning — tightening or breaking the call.
Utah holds at 638 measles cases as the national tally crosses 1,842 — the PAHO elimination-status review is six months out and the Mountain West cluster is the parallel architecture to Bangladesh.
Nineteen days after his death, the named fellowships and the textbook Eugene Braunwald built still produce next year's cardiologists; the mentorship infrastructure is the obit.
Thirty days out from June 10, the NICE reconsultation on donanemab and lecanemab is running without new UK manufacturer evidence; the Cochrane indictment still owns the meta-analytic ground.